cell lungcancer, and melanoma.' Lymphoma may alsocause neoplastic meningitis, termedlymphomatous carcinomatosis. Typically, survivalis measured in weeks withouttreatment and approaches 3-6 months with traditional treatments.' Treatments commonly utilizedfor the managementof leptomeningeal carcinomatosis include radiation, systemic chemotherapy, and intrathecal chemotherapy. Drugs currently utilized intrathecally include cytarabine,liposomalcytarabine, methotrexate, and thiotepa. According to the National Comprehensive Cancer Network, patients with leptomeningeal carcinomatosis may be considered for eithersupportive care, fractionated external beam radiation to symptomatic sites,or intrathecal chemotherapy,' Patients with lymphomatouscarcinomatosis haveadditional options, including steroid administration and systemicchemotherapy with high-dose methotrexate,' Despite theseconventional therapies, response still remains low.
Due to the presence of the blood-brain and blood-cerebrospinal barriers, it is difficult for systemically administered chemotherapy to penetrate into the site of leptomeningeal disease. Further hindering penetration of chemotherapy into the CSF are the adverse effects associated with the high doses of systemically administered drugs required to achieve adequate CNS concentrations. Many agents, including monoclonal antibodies, tend to be large moleculesand those weighing above 200 kDA have minimal penetration into the CSF. Due to low CNS penetration of most chemotherapy,the CNS often acts as a sanctuary site for tumor cells. For these reasons the desired route of administration is intrathecal; however,response is generally short lived and patients may develop adverse effects such as arachnoiditis from the chemotherapy.
More recently, intrathecal administration of 2 monoclonal antibodies has been investigated, representing. a novel and targeted treatment for leptomeningeal carcinomatosis.Intrathecal trastuzumab, an anti-human epidermal growth factor receptor (HER2) monoclonal antibody,has been utilizedand reported in HER2-positive breast cancer. Additionally, intrathecal rituximab, an anti-CD20 monoclonal antibody, has been investigated in B-cell lymphoma and leukemia. Though much of the data are preliminary, there has been interestin utilizingsuch novel agents in the management of leptomeningeal carcinomatosis.
Another emerging optionfor the treatment of HER2-positive breastcancerwith leptomeningeal carcinomatosis is the oral tyrosine kinaseinhibitor lapatinib. It showspromise for leptomeningeal carcinomatosis, as it is a small molecule « 1 kDa) able to penetrate the blood-brain barrier.However,2 Phase2 trials (EGF105084 and NCI-6969) thatstudied lapatinib monotherapy for leptomeningeal carcinomatosis were bothterminated prematurely, as they failed to meet theirprimaryendpoints.vThe modesteffects observed in clinical trialsmaybe attributed to efflux transporters thatpumpthedrug out of theCNS. Lapatinib is notdiscussed in thisreview.
LITERATURE REVIEW
A search ofMEDLINE (l966-July 2010) and International Pharmaceutical Abstracts (l970-July 2010) was performed using the search terms intrathecal, trastuzumab, rituximab, and monoclonal antibody. Relevant articles were identified and references of these articles were reviewed for additional reports. Meeting abstracts of the American Society of Clinical Oncology, the San Antonio Breast Conference, the American Association for Cancer Research, and the American Society of Hematology were also searched. Reportsmost pertinentto the use of intrathecal trastuzumab and rituximab are reviewedhere.
HER2-Posltlve Breast Cancer and Intrathecal Trastuzumab
Trastuzumab plays a central role in the treatment of HER2-positive breast cancer and has been shown to increase survival. Whether due to this increase in survival, the lack of trastuzumab penetration into the CNS, or the aggressivenatural history of HER2-positive breast cancer, patients receiving trastuzumab may have a higher incidence of CNS metastases.' It has been shown that CSF concentrations of trastuzumab are 300-to 4OO-fold lower than serum concentrationsf" These concentrations may be increased by inflammation or whole-brain radiation therapy; however,concentrations stilIremain between In6 and 1/49 of those in plasma and may not be consistently high enough to have a therapeutic effect.' With the known activity of trastuzumab and difficulty in achieving adequate CNS concentrations, intrathecal administration has been considered.
In a rat model, trastuzumab was administered via direct intracerebral microinfusion or intraperitoneally after transplantationof HER2 breast cancer cells into the cerebrum/ Among rats receiving systemic (intraperitoneal)trastuzumab, survival was 265 days, while the median survival of those receiving intracerebral trastuzumab was 52 days. No toxicity was evident in those receiving intracerebral trastuzumab. Another animal model utilizing cynomolgus monkeys evaluated the toxicity and pharmacokinetics of intrathecal trastuzumab," Doses equated to approximately 3.4-to 67-fold higher thandosesused in humanclinical case reports. Notably, upon neurologic, clinical, and anatomic pathology examinations, no trastuzumab-related adverseeffectsoccurred. CSFconcentrations attained weremuchhigher thanin clinical models, as dosesin thisanimaI model were muchhigher. However, therewas large variation in CSF concentrations.The authors attributed this variation to uneven distribution of drugthroughout theCNS and rapid transfer of trastuzumab fromtheCSF intothe serumafterintrathecal administration. In additionto these animal studies,there are a limitednumber of reportsin which intrathecal trastuzumab was utilized in humans (Table 1 1 
The use of intrathecaltrastuzumabhas been described in 8 case reports involving patients with leptomeningeal carcinomatosis following HER2-overexpressing metastatic breast cancer,'?'? Patients were administered intrathecal trastuzumab as salvage therapy after failing extensive treatmentwith either neurosurgery, systemicchemotherapy, intrathecal chemotherapy, or whole-brain radiation; in many,a combination of the 4 was utilized. Intrathecal trastuzumab was used as monotherapy in 4 casesand givenconcurrently with intrathecal methotrexate or intrathecal thiotepain the other 4. Doses of trastuzumab ranged from 5 to 100 mg and were repeated after as little as 3 days in 1reportto as longas 3 weeksin others.IO.I2.14 The mostcommon schedulewas 20-30 mg weekly. All doses, including doses up to 100 mg, and schedules were well tolerated. In fact, an autopsy failed to reveal any toxicity, including arachnoiditis, in 1 case report,"
Intrathecal therapy with trastuzumab resulted in noticeable reliefof clinical symptoms (overflow incontinence, paraparesis of the legs, mental status changes,headaches, ataxia, and visual impairment)for 7 of the 8 patients.Two patients showed a decrease or disappearance of brainlesions on magnetic resonanceimaging,":" The duration of diseasecontrol from the initiation of intrathecal trastuzumab rangedfrom 39 days to greater than 72 months, with 6 patients surviving greater than 5 months.P" Interestingly, the patientwho died at day 39 of intrathecal trastuzumab treatment died due to progression of visceral metastases and was consideredto be Intrathecal Rituximab andTrastuzumab in Leptomeningeal Carcinomatosis in remission with regard to the leptomeningeal carcinomatasis.'?Tumor cell counts were also found to be eliminatedor substantially decreased in 4 of 5 patients. IO,IJ.J4.J7
In 2 reports, response appeared to be related to dose.1 4.Js In 1 of these, the patient was started on 20 mg weekly and benefits from intrathecaltrastuzumab were not appreciated until doses were increased past 30 mg." Intrathecal trastuzumab was coadministered with intrathecal thiotepa and the greatest response occurred when both trastuzumab and thiotepadoses were increasedto 50 and 12mg, respectively. A second report also suggests that trastuzumab at doses higher than 20-30 mg may result in increasedefficacy," These cases, as well as other preclinicaldata, hint at a dose-response relationship and the possibility of a synergistic relationship with trastuzumaband thiotepa,"
Two patients had CSF concentrations of trastuzumab measured prior to dose administration. Intrathecal therapy showed a substantial increase in CSF concentrations of trastuzumab compared with systemic therapy alone. Measured CSF concentrations after intrathecal trastuzumab peakedat 3400 and 6425 ng/mLduringtherapy.lO,13 Although CSF concentrations werehigherthanthoseseenwithsystemically administered trastuzumab, concentrations were still lower thanserumconcentrations (34,274and 82,303 ng/ml., respectively). Both reports utilized a maximum dose of 20 mg and, given the lack of toxicity (evenat 100 mg) and relatively low CSF concentrations, higherdoses may be reason- 
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Recently, results of a small pilot study utilizing intrathecal trastuzumab have been reportedin abstractform," Sixteen patients (11 with glioblastoma multiforme, 4 with breast cancer, and 1 with medulloblastoma) were treated with 4 treatments of intrathecal trastuzumab 20-60 mg either weekly or every other week. Responders and those with stable disease continuedtherapy every other week indefinitely or until neurologic progression.Ten patients responded (7 with glioblastoma multiforme, 2 with breast cancer, I with medulloblastoma),with response durations lastingfrom 4 to more than 14 weeks. Despitethe relatively small sample size and heterogeneous patientpopulation, over 60% of the patients receiving intrathecaltrastuzumab responded, with 2 of the 4 patients with breast cancer responding.At the time this abstract was presented,patients continued to respond,making response durationdifficult to determine from this analysis.Final results are necessary in order to determinetrastuzumab's full effect in this study.
Based on this pilot study and the reviewedcase reports, intrathecal trastuzumab appears to be a promising therapy. Its use led to survivals ranging from 4 weeks to more than 72 months,and most patients had resolution of leptomeningeal carcinomatosis symptoms. Noneof the reported patients experienced clinical toxiceffects. These observed resultsmust be interpreted with caution given the heterogeneity in the doses, schedules, and concomitant therapies used in the patients.Althoughit is difficult to distinguish betweenthe effectsof systemic therapies and other intrathecal therapies in these reports, intrathecal trastuzurnab deserves further investigation in the setting of leptomeningeal carcinomatosis due to HER2-positive breastcancer in order to determinethe biologically optimal dose,schedule, andplacein therapy.
Lymphoma andIntrathecal Rltuximab
Similar to the interest in intrathecal trastuzumab, the useof intrathecalrituximab for the treatment of CNS lymphoma and leukemia has garneredattention. The majority of B-cell non-Hodgkin's lymphomas and B-cellieukemias express the CD20 antigen, and systemic rituximab (anti-CD20 monoclonal antibody) has beenshownto be effective in theirtreatment.Rituximab has been shownto increase survival; however,it has not been associated with a decrease in the risk of secondaryCNS occurrence. 20 ,21 The lack of an effect in decreasing the riskof CNSdissemination may be due to the relatively low penetrationof rituximab into the CNS. In fact, CSF concentrations of rituximab after systemic administration have shown to be only 0.1% of the serum concentrations," Like trastuzumab, the activity of rituximabcoupled withrelatively poorCNS penetration led to the currentinterest in the intrathecal use of this agent.An animal modelutilizing intrathecal rituximab in cynomolgus monkeys showed this intervention to be well tolerated, with no clinical evidence of toxicity."In addition to this animal model,the use of intrathecal rituximab has been reported in case reports, case series, and a Phase I trial (Table 223-32) .
Seven individual case reports have been published studying the use of intrathecal rituximab for CNS lyrnphoma.P" Doses ranged from 10 to 40 mg and were most commonly initiated at 10 mg and increased to the highesttolerated dose or untilacceptable clinical response occurred. All 7 patients showedresponse in tumorcell clearance. Cytologic responses were also accompanied with symptomatic improvements in 4 casesand included neurologic improvements, disappearance of seizures and headaches, and cognitive improvement. 24 ,2S,27,28 Only 1 report described progression of CNS lymphoma." Survival in these7 case reports rangedfrom 4 months to greater than 35 years. Threeof7 patients received high-dose chemotherapy withautologous stemcellrescue after receiving intrathecal rituximab. 23 ,24,29 Adverseeffectsreported include neuropathic pain, headache, cramps, back pain, and leg weakness. Infusion reactions characterized by tingling sensations in the extremities, transient upwardgaze of eyes, nausea,chills,hypotension, and disorientation were reported. Thesereactions occurred withthe 4O-mg dosesand did not produce any long-lasting sequelae.
The results of a case series and a prospective study investigating the safety and efficacyof intrathecal rituximab have also been reported. In the case series (n =6), doses were intensified (10-40 mg) duringthe courseoftreatrnent and were given as frequently as 3 times weekly." Final outcomes weredescribed as total clearing of malignant cells in 1 patient, disease progression in 2 patients, and minor response in 1 patient. The prospective study included7 pediatric patients with B-cell acute lymphoblastic leukemiarefractory to triple intrathecal therapy (methotrexate, cytarabine, hydrocortisone) with or without radiation," Patients received intrathecal rituximab 10 mg twice weekly for 4 weeks.After24 months, 5 patients remained in complete remission. Patients receiving rituximab showed no signs of neurotoxicity. Of the 13patients studied in bothreports, only 1 had neurologic complications." This patient suffered from Burkitt's lymphoma and experienced a severe pain attack and paraparesis. This was thoughtto be relatedto a high tumor burden and rapidtumorcell lysis. Anotherpatient experienced nausea/chills with a 4O-mg dose immediately after administration. Survival in both reports ranged from 2 months to more than 24 months.Similarto the small study with trastuzumab, it is difficult to determinethe drug's true potential from these studies.Given the studies' small size, along withthe differing dosesand administration schedules, more data are necessary. However, as seen in both the case reports and the case series, it appears that doses of 40 mg may increase the likelihood of adverse effects.
Intrathecal rituximab has been investigated in a Phase 1 study that soughtto define its safety, pharmacokinetics, and efficacy." Doses of 10-50 mg were administered to 10 patients. Rituximab was administered over 1-5 minutes either diluted with NaCI 0.9% or as undilutedstock solution. Prior to administration, patientsreceived acetaminophen, diphenhydramine, and famotidine or cimetidine and had 5 mL of CSF removed. None of the 8 patients receiving 10and 25 mg exhibited signs of major toxicity. Both patientsreceiving50 rng suffered from toxicities (hypertension, diplopia, nausea/vomiting, chest pain, and tachypnea). Symptoms resolved within 20 minutes with medical management.Over-a11,6 patients had cytologicresponses, 4 of whom had complete responses. The longest cytologic response was 9 months, while survival ranged from 1.1 week to more than 134 weeks. Mean I-hourpostdose CSF concentrations were 214 pg/mL with the to-mg dose and 472 pg/mL with the maximum tolerated dose of 25 mg. These concentrations are similar to peak concentrations in the serum after intravenous injectionof rituximab. Concentrations rapidlydeclinedafter the dose, with a half life of 34.9 hours at the 25-mg dose. This rapiddecline in concentrations was alsoobserved in I of the case reports," As demonstratedpreviously with systemic rituximab for lymphoma, response may correlate with sus-Intrathecal Rituximab and Trastuzumab in Leptomeningeal Carcinomatosis tained rituximab concentrations," This Phase 1 study, along with the aforementioned small studies and 7 case reports , has revealed the potential of intrathecal rituximab. Although toxicities have been described, the majority have been with doses of 40 mg or greater and have been manageable. Similar to trastuzumab, additional data are necessary to determine the biologically optimal dose and schedule. Administration of doses more frequently may help mitigate the rapid removal of drug fromthe CSF; however, this schedule requires validation in a clinical trial.
Practical Considerations
It is important to use sterile water when preparing trastuzumab for intrathecal administration and not the provided diluent (bacteriostatic water) to prevent the intrathecal administration of preservative, which can lead to neurotoxicity or anaphylaxis." Tonicity of the drug diluted in water was not an issue in the described case reports. Given the lack of the preservativeand the route of administration, trastuzumab for intrathecal use should be administeredimmediately after preparation despite the reported physical and chemical stability of 48 hoursunderrefrigerated conditions and 24 hours at room temperature whenprepared withsterile water," One case reportgave details regarding the preparation,in which 150mg oftrastuzumab(trastuzumab is available in 150-mg vials in the UK and Australia)was diluted with7.2 mL of sterile water,"Rituximab was prepared in the Phase 1 trialby diluting the stocksolution with preservativefree NaCI 0.9% in a 1:1 ratiofor the 10-and 25-mgdosages or without dilution for the 50-mg dosage." All rituximab doses were administered slowly over a period of 1-5 minutes. Intrathecal trastuzumab and rituximab were delivered by either lumbar puncture or via an Ommaya reservoir in these reports. It is unknown whether the delivery method would influence outcome; however, administration of intrathecal agents via an Ommaya reservoircompared to repeated lumbarpunctures maybe safer. 35 ,36
Summary
The prognosis for leptomeningeal carcinomatosis is quite grimwithconventional therapies. Available options are limited to supportive care,radiation, or intrathecal chemotherapy. Additional options, suchas steroids and systemic chemotherapy with high-dose methotrexate, are available for lymphomatous carcinomatosis. Withthepoorefficacy of these therapies and the frequency of leptomeningeal carcinomatosis diagnosis increasing, oncologists havechallenging decisions to make. The blood-brain and blood-cerebrospinal barriers are believed to be theprimeculprits preventing the accumulation of drug at the siteof leptomeningeal carcinomatosis. Consequently, while intravenous trastuzumab and rituximab are first-line agents for theirrespective disease states, theirefficacy is poor in leptomeningeal carcinomatosis, as they are unableto penetrate these barriers. Theselargemonoclonal anti" bodies requireadditional assistance to reachthe site of leptomeningeal carcinomatosis. One way is to deliver them directly into the siteof CNS disease via intrathecal administration. The availabledata suggestthat intrathecal trastuzumab andrituximab maybe safeandeffective andmitigate the poor penetrationassociated with systemic administration. Both agents haveresulted in longperiods free from diseaserelated symptoms thatmay impact quality of life.
Trastuzumab wastolerated at doses ranging from5 to 100 mg. CSF concentrations were determined with the 20-mg dose and found to be higher than with systemic therapy alone; however, CSF concentrations were lowerthan serum concentrations obtained with systemic therapy. Whether higherdoses would yield higherCSF concentrations is unknown at thistimeand needs to be addressed in the setting of a Phase 1 trial. At this time, basedon the available data, no recommendations can be made regarding a standard dose.
Rituximabwas toleratedat doses ranging from 10 to 30 mg. CSF concentrations in the Phase 1 trial were similarto those obtained in the serum withsystemic therapy. Contrary to the available data with trastuzumab, rituximab doseescalationabove 30 mg resulted in adverse effects. At this time, moredata are necessary to determine intrathecal rituximab's placein therapy; however, if the drugis utilized, a doseof 25 mg would be reasonable based on the Phase 1 data. In patientswith a very largeCNS tumor burden,dose escalation (starting with 10 mg and increasing to 25 mg) may be considered to prevent adverse effects fromtumorlysis.
Intrathecal therapy showspromisebut is stillin its infancy. The reports discussed above illustrate the feasibility of intrathecal administration of rituximab and trastuzumab and encourage further investigation. Larger studies are needed to determine biologically optimaldoses, frequency, and duration of therapy. A patientrefractory to other available treatments may benefit from intrathecal trastuzumab or rituximab; however, this approach remains investigationaluntil more data are available.
EXTRAcro OBJETIVO: Revisar la evidencia del uso de rituximaby trastuzumab intratecalen el tratamientode la carcinomatosisleptomenfngea (CL).
FUENTES DE INFORMACION: Se realiz6 una busqueda bibliograficaen
MEDLINE (l966-julio de 2010) Yen AbstractosFarmaceuticos lnternacionales (l970-julio de 2010) con los terminos debtisqueda intratecal,trastuzumab,rituximaby anticuerposmonoclonales. Asirnismo,se realizaronbiisquedasen los extractosde las conferencias de la Sociedad Americanade OncologfaClfnica.Ias Confereneias de Mama de San Antonio,la Asociaci6nAmericanapara la Investigaci6n en el Cancer, y la Sociedad Americanade Hematologfa,
SELECCION DE FUENTES DE INFORMACION Y IIttTooo DE EXTRACCION DE
INFORMACION: Se revisaronlas publicacionesy se incluyeronaquellos artfculosque tratabanel uso de rituximaby trastuzumabpor via intratecalpara un total de un ensayo clfnicode fase 1.2 pequeiios estudios prospectivos,una serie de casos, y 15casos clfnicos, SINTESIS: El tratarnientode la CL es complicadodebido a la barrera hernatoencefalica. Numerosasterapiasadministradaspor vfa sistemica no penetrandirectamenteallugar de la enfermedad leptomenfngeay se han mostradocomo inefectivas.La administraci6nintrateeal(l1) de dos anticuerposmonoclonales(trastuzumaby rituximab)ha sido investigada en varios casos clfnicosy series de casos. Ademas, rituximab IT ha sido objeto de investigaci6nen un estudio de fase I. La supervivenciatras el tratamientocon trastuzumabIT oscil6 entre 39 dfas y mas de 72 meses y fue bien tolerado sin eventos adversos atribuidosal farmaco,Lasdosis utilizadasen estos informes variaron entre 5 y 100 mg. La supervivencia tras el tratamientocon rituximab IT oscil6 entre 1.1 semanas y mas de 35 aiios.En el ensayo de fase I, la dosis maxima toleradade rituximab fue de 25 mg y con un 60% de respuesta.Cuatro de los seis pacientes con respuesta presentaronuna respuestacompleta. RituximabIT mostr6 una toxicidadmenor que se resolvi6 rapidamentesin efectos a largo plazo.
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